Explore the vast range of titles available.

ObjectiveTo determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache.MethodsIn this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes.ResultsOf 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 ± 35.3 to 16.8 ± 13.9 (p < 0.001), while monthly headache days decreased from 25.4 ± 5.4 to 14.1 ± 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed.ConclusionsErenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.

We describe a 63-year-old man diagnosed with sporadic Creutzfeldt-Jakob disease (sCJD), specifically sporadic fatal insomnia, confirmed through real-time quaking-induced conversion (RT-QuIC) analysis of cerebrospinal fluid and polysomnography. He presented with rapid cognitive decline, behavioural changes, sleep disturbances and dysautonomic symptoms. Initial MR imaging, electroencephalogram and cerebrospinal fluid analyses were inconclusive, highlighting the difficulty in diagnosing this rare subtype of CJD. Clinical evaluation is fundamental in defining the diagnosis of sCJD. When clinical suspicion is strong, the diagnostic work-up should be continued. In this case, the combination of comprehensive clinical evaluations and advanced diagnostic tools, including RT-QuIC and polysomnography, proved essential in making a definitive diagnosis.

Lead halide perovskite nanocrystals (LHP-NCs) embedded in a plastic matrix are highly promising for a variety of photonic technologies and are quickly gaining attention as ultrafast, radiation-resistant nanoscintillators for radiation detection. However, advancements in LHP-NC-based photonics are hindered by their well-known thermal instability, which makes them unsuitable for industrial thermally activated mass polymerization processes - crucial for creating polystyrene-based scintillating nanocomposites. In this study, we address this challenge by presenting the first thermal nanocomposite scintillators made from CsPbBr3 NCs passivated with fluorinated ligands that remain attached to the particles surfaces even at high temperatures, enabling their integration into mass-cured polyvinyl toluene without compromising optical properties. Consequently, these nanocomposites demonstrate scintillation light yields reaching 10,400 photons/MeV, sub-nanosecond scintillation kinetics, and remarkable radiation resilience, able to withstand gamma radiation doses of up to 1 MGy. This performance not only meets but also exceeds the scintillation of plastic scintillators, despite the radiation-induced damage to the host matrix.